002728 Stock Overview
Engages in the research and development, production, and sale of Chinese patent medicines, pharmaceutical preparations, raw materials, and products in the People’s Republic of China. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 3/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 4/6 |
My Notes
Capture your thoughts, links and company narrative
Teyi Pharmaceutical Group Co.,Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥9.09 |
| 52 Week High | CN¥13.29 |
| 52 Week Low | CN¥6.79 |
| Beta | 1.58 |
| 1 Month Change | 0.66% |
| 3 Month Change | 30.04% |
| 1 Year Change | -27.82% |
| 3 Year Change | 10.80% |
| 5 Year Change | 5.67% |
| Change since IPO | 76.75% |
Recent News & Updates
Recent updates
We Think Teyi Pharmaceutical GroupLtd (SZSE:002728) Can Stay On Top Of Its Debt
Jun 06
Why Teyi Pharmaceutical GroupLtd's (SZSE:002728) Shaky Earnings Are Just The Beginning Of Its Problems
Apr 26Teyi Pharmaceutical Group Co.,Ltd's (SZSE:002728) Shares Bounce 29% But Its Business Still Trails The Market
Mar 06Here's Why We Think Teyi Pharmaceutical GroupLtd (SZSE:002728) Is Well Worth Watching
Feb 27Shareholder Returns
| 002728 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | -5.6% | -4.3% | -3.5% |
| 1Y | -27.8% | -3.4% | 10.9% |
Return vs Industry: 002728 underperformed the CN Pharmaceuticals industry which returned -3.4% over the past year.
Return vs Market: 002728 underperformed the CN Market which returned 10.9% over the past year.
Price Volatility
| 002728 volatility | |
|---|---|
| 002728 Average Weekly Movement | 7.7% |
| Pharmaceuticals Industry Average Movement | 7.4% |
| Market Average Movement | 8.7% |
| 10% most volatile stocks in CN Market | 12.8% |
| 10% least volatile stocks in CN Market | 5.7% |
Stable Share Price: 002728 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 002728's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 1,243 | n/a | www.tczy.com.cn |
Teyi Pharmaceutical Group Co.,Ltd engages in the research and development, production, and sale of Chinese patent medicines, pharmaceutical preparations, raw materials, and products in the People’s Republic of China. The company offers cough and phlegm, kidney, anti- infection, cardiovascular and cerebrovascular, and digestive system drugs, as well as pediatrics, dermatology, tuberculosis, respiratory, rheumatology, nephrology, and endocrinology medicines. Its chemical raw materials and products include aluminum carbonate, phenytoin, ferrous sulfate, glacial acetic acid, calcium chloride, sodium chloride, bismuth series, citric acid series, zinc sulfate, etc. The company was formerly known as Guangdong Taicheng Pharmaceutical Co., Ltd.
Teyi Pharmaceutical Group Co.,Ltd Fundamentals Summary
| 002728 fundamental statistics | |
|---|---|
| Market cap | CN¥4.53b |
| Earnings (TTM) | CN¥70.70m |
| Revenue (TTM) | CN¥777.52m |
64.0x
P/E Ratio5.8x
P/S RatioIs 002728 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 002728 income statement (TTM) | |
|---|---|
| Revenue | CN¥777.52m |
| Cost of Revenue | CN¥431.34m |
| Gross Profit | CN¥346.18m |
| Other Expenses | CN¥275.48m |
| Earnings | CN¥70.70m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.14 |
| Gross Margin | 44.52% |
| Net Profit Margin | 9.09% |
| Debt/Equity Ratio | 36.7% |
How did 002728 perform over the long term?
See historical performance and comparisonDividends
3.9%
Current Dividend Yield290%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/20 23:12 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Teyi Pharmaceutical Group Co.,Ltd is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Suqing Huang | Everbright Securities Co. Ltd. |